TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-13.7x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -35.56% |
| Q3 2025 | -4.71% |
| Q2 2025 | 9.55% |
| Q1 2025 | 1.48% |
| Q4 2024 | 11.77% |
| Q3 2024 | -2.29% |
| Q2 2024 | 8.13% |
| Q1 2024 | 10.94% |
| Q4 2023 | -1.47% |
| Q3 2023 | 7.13% |
| Q2 2023 | -2.53% |
| Q1 2023 | 39.57% |
| Q4 2022 | 3.81% |
| Q3 2022 | 3.70% |
| Q2 2022 | -1.33% |
| Q1 2022 | 16.51% |
| Q4 2021 | -11.25% |
| Q3 2021 | 31.52% |
| Q2 2021 | 47.17% |
| Q1 2021 | 23.05% |
| Q4 2020 | 2.60% |
| Q3 2020 | 29.12% |
| Q2 2020 | 4.75% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |